Scribd
Upload
34 views3 pages

Coronavirus Vaccine Development Challenges

CEPI announced funding for four vaccine candidates to protect against the 2019 coronavirus two weeks after the outbreak began in Wuhan, China. While these funded projects use promising new approaches, none have licensed a vaccine yet. Even if vaccine development is expedited, mass production capacity is still needed to manufacture enough doses. Past vaccines for diseases like measles and HPV required large and sustained funding to outweigh production costs after initial outbreaks ended. Patents on vaccine development processes can also impede creation of new vaccines due to weak protection of the final product alone.

Uploaded by

Jes López
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
34 views3 pages

Coronavirus Vaccine Development Challenges

CEPI announced funding for four vaccine candidates to protect against the 2019 coronavirus two weeks after the outbreak began in Wuhan, China. While these funded projects use promising new approaches, none have licensed a vaccine yet. Even if vaccine development is expedited, mass production capacity is still needed to manufacture enough doses. Past vaccines for diseases like measles and HPV required large and sustained funding to outweigh production costs after initial outbreaks ended. Patents on vaccine development processes can also impede creation of new vaccines due to weak protection of the final product alone.

Uploaded by

Jes López
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 3

Coronavirus

Vaccine
English VI

Jesarel Isai López Arizmendi


Two weeks after China announced on Jan. 7 that the recent coronavirus
had ignited the fast-growing occurrence of pneumonia causes at the
municipality of Wuhan, CEPI announced support for three attempts to
create a vaccine to protect against this virus, presently known as 2019-
nCoV. One week later, it added the fourth. Only days after this, it
announced major vaccine manufacturer GSK could provide its patented
adjuvants — compounds that increase the potency of vaccines — to be
used in this reaction. But up to now, most of the CEPI-funded campaigns
are concentrated on partners that don’ ’t get the production facilities to
create the commercial product in volume. They consider Inovio, the
contract between Moderna and the National association of Allergy and
contagious Diseases; CureVac; also as the University of Queensland, in
country. All have advanced approaches that provide the hope of new rate
to the growth of the vaccine person. But none of these companies has
even licensed the vaccine.
Even if vaccine growth can be sped up within the outbreak, that doesn’ ’t
think that production power is also there to get the vaccine to measure. For
instance, a research group that is working on the coronavirus vaccine
partners with biotech corporations, government offices, and the university.
They want to create current partnerships to be able to create mass
amounts of vaccines. Once the crisis is over and there aren’ ’t huge funds
coming from governments responding to the situation, there isn’ ’t more
money in producing vaccines. Some of those viruses that presently get the
vaccine include measles, polio and being papillomavirus (HPV ) . In these
instances, the possible destruction of those diseases going out of hand
outweighs the costs of producing the vaccine.
The filing of patents on vaccine growth procedures will also be regarded as
an impediment to the growth of new vaccines. Because of the weak
protection provided through the document on the last product, The
protection of this design regarding vaccines is often created through the
patent of procedures used in the process of new vaccines , too as the
security of privacy. (Hardman Reis T, 2006).

Coronavirus vaccines may take inactivated coronavirus, go attenuated


coronavirus, or S protein-based. Also, there exist even vectored vaccines,
DNA vaccines, and combining vaccines against coronaviruses. Vaccines
targeting various animal CoVs have been produced, and some have been
proven to take efficacious at preventing viral transmission. Still, the
phenomenon of increased disease following vaccination has been
observed in cats upon transmission with feline infectious peritonitis virus
following past transmission, vaccination, or passive transport of protein.

Jesarel Isai López Arizmendi

Brenda Ibarra Sánchez

You might also like